Abemaciclib-loaded ethylcellulose based nanosponges for sustained cytotoxicity against MCF-7 and MDA-MB-231 human breast cancer cells lines

Abemaciclib (AC) is a novel, orally available drug molecule approved for the treatment of breast cancer. Due to its low bioavailability, its administration frequency is two to three times a day that can decrease patient compliance. Sustained release formulation are needed for prolong the action and...

Descripción completa

Detalles Bibliográficos
Autores principales: Anwer, Md. Khalid, Fatima, Farhat, Ahmed, Mohammed Muqtader, Aldawsari, Mohammed F., Alali, Amer S., Kalam, Mohd Abul, Alshamsan, Aws, Alkholief, Musaed, Malik, Abdul, Az, Alanazi, Al-shdefat, Ramadan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257851/
https://www.ncbi.nlm.nih.gov/pubmed/35812154
http://dx.doi.org/10.1016/j.jsps.2022.03.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257851/
https://www.ncbi.nlm.nih.gov/pubmed/35812154
http://dx.doi.org/10.1016/j.jsps.2022.03.019

Ejemplares similares